je.st
news
Tag: announces firstquarter
Merck Announces First-Quarter 2014 Financial Results
2014-04-29 13:00:00| Merck.com - Financial News
Dateline City: WHITEHOUSE STATION, N.J. First-Quarter 2014 Non-GAAP EPS of $0.88, Excluding Certain Items; GAAP EPS of $0.57; Confirms 2014 Full-Year Non-GAAP EPS Target of $3.35 to $3.53, Excluding Certain Items; GAAP EPS Range of $2.15 to $2.47 Worldwide Sales were $10.3 Billion, a Decrease of 4 Percent, Reflecting Unfavorable Impact of Patent Expiries and a 2 Percent Unfavorable Impact from Foreign Exchange Strategic Initiatives Drove Cost Reductions and Portfolio Divestitures, Generating First-Quarter 2014 Benefits Sales of REMICADE, SIMPONI and ISENTRESS, as well as Diabetes and Vaccines Franchises Grew FDA Approved GRASTEK and RAGWITEK Sublingual Allergen Extract Immunotherapy Tablets and Accepted Filings for V503 and Suvorexant; Company Announced Progress in Key Clinical Programs Including HCV and HIV Repurchased $7.5 Billion of Common Stock Over Previous 12 Months as Part of Ongoing Share Repurchase Program WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2014. Language: English Contact: MerckMedia:Steve Cragle, 908-423-3461Lainie Keller, 908-423-4187orInvestors:Joe Romanelli, 908-423-5185Carol Ferguson, 908-423-4465 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
financial
announces
merck
La-Z-Boy Announces Fiscal 2014 First-Quarter Conference Call
2013-08-09 14:02:39| Furniture - Topix.net
La-Z-Boy Incorporated will report its fiscal 2014 first-quarter operating results after the close of trading on the New York Stock Exchange on Tuesday, August 20, 2013, and will hold its quarterly investor conference call at 8:30 a.m. Eastern Time the following day, Wednesday, August 21, 2013.
Tags: call
conference
fiscal
announces
Merck Announces First-Quarter 2013 Financial Results
2013-05-01 13:00:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. 2013 First-Quarter Non-GAAP EPS of $0.85, Excluding Certain Items; GAAP EPS of $0.52 Worldwide Sales were $10.7 Billion, a Decrease of 9 Percent Primarily as a Result of Patent Expiries, and Including a 2 Percent Unfavorable Impact from Foreign Exchange Growth in Vaccines, Immunology, HIV, Animal Health and Consumer Care Products Received Breakthrough Therapy Designation for Lambrolizumab, an Investigational Candidate for Advanced Melanoma; Five Products Currently Under Regulatory Review Announced New $15 Billion Share Repurchase Program; Plans to Repurchase Approximately $7.5 Billion of Common Stock over the Next Twelve Months Revises 2013 Full-Year Non-GAAP EPS Target to $3.45 to $3.55, Excluding Certain Items; Revises GAAP EPS Range to $1.92 to $2.16 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2013. $ in millions, except EPS amounts FirstQuarter2013 FirstQuarter2012 Language: English Contact HTML: MerckMedia Contacts:Steve Cragle, 908-423-3461Kelley Dougherty, 908-423-4291orInvestor Contacts:Carol Ferguson, 908-423-4465Alex Kelly, 908-423-5185 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
financial
announces
merck
Sites : [1] [2]